Merck & Company, Inc.

Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh has 4.98T shares outstanding.

As of June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh maintains a current ratio of 1.32, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 128.40, indicating elevated leverage, while an interest coverage ratio of 7.52 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh posted a return on equity (ROE) of 6.98, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.61 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.57, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.55, useful for judging operating efficiency across full business cycles. The company generates approximately 29.49M in revenue per employee across its workforce of 75,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.81 indicates how many times Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh recorded 92.34B in income tax expense. That works out to an effective tax rate of 46.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 197.63B, leaving 105.43B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh generated 2.21T in revenue and converted that into 105.43B in net income, yielding earnings per share of 0.02. EBITDA reached 435.07B, while operating income came in at 232.09B.

As of June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh holds 237.27B in cash and equivalents against 1.79T in total debt, resulting in a net debt position of 1.56T. Total book value stands at 1.39T, with working capital of 297.32B providing operational flexibility.

Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh produced 663.44B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh posted a gross margin of 72.97, reflecting its pricing power and cost economics. The operating margin of 10.49 and net profit margin of 4.77 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh paid dividends of 0.06 per share. The dividend payout ratio of 262.18 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.